Incidence of Primary Progressive Apraxia of Speech and Primary Progressive Aphasia in Olmsted County, MN, 2011-2022.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
27 Aug 2024
Historique:
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: ppublish

Résumé

No epidemiologic studies have formally assessed the incidence of primary progressive aphasia (PPA) and primary progressive apraxia of speech (PPAOS). Thus, we decided to assess the incidence of these disorders in Olmsted County, MN, between 2011 and 2022, and to characterize clinical, radiographic, and pathologic characteristics of these patients. This was a retrospective examination of data from a population-based cohort of patients with PPA and PPAOS prospectively identified in Olmsted County, MN, from 2011 to 2022. The incidence of PPA among adults (older than 18 years) was calculated for Olmsted County as the number of patients per 100,000 person-years during the study period. The adult population of Olmsted County was determined by the annual catchment population reported by the Rochester Epidemiological Project for each year 2011-2022. A behavioral neurologist verified the clinical diagnoses and determined subtypes. We identified 10 patients (60% female) within the study period (median age of symptoms onset: 70 years; range: 66-73), 8 with PPA and 2 with PPAOS. Of the 8 patients with PPA (6 female patients, 2 male patients), 2 met criteria for non-fluent variant PPA (nfvPPA), 3 for logopenic variant PPA (lvPPA), and 3 for semantic variant (svPPA). Speech evaluation confirmed the clinical diagnoses in all patients and all showed typical imaging findings consistent with their respective subtype. Six patients (2 PPAOS, 2 nfvPPA, 2 lvPPA) died and 3 underwent autopsy (2 PPAOS, 1 nfvPPA), confirming the pathologic diagnosis of progressive supranuclear palsy. The incidence of PPA + PPAOS was 0.70 persons per 100,000 person-years (95% CI 0.34-1.29 persons per 100,000) during the study period. The incidence of PPAOS was 0.14 persons per 100,000 person-years (95% CI 0.02-0.55 persons per 100,000), whereas for the 8 patients with PPA, the incidence was 0.56 persons per 100,000 person-years (95% CI 0.24-1.10 cases per 100,000). The incidence of nfvPPA was 0.14 persons per 100,000 person-years (95% CI 0.02-0.55), 0.21 persons per 100,000 person-years (95% CI 0.04-0.61) for lvPPA, and 0.21 persons per 100,000 person-years (95% CI 0.04-0.61) for svPPA. As a group, PPA and PPAOS are a relatively rare group of diseases. PPAOS has a slightly lower incidence than PPA as a group but similar incidence to the individual PPA variants.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
No epidemiologic studies have formally assessed the incidence of primary progressive aphasia (PPA) and primary progressive apraxia of speech (PPAOS). Thus, we decided to assess the incidence of these disorders in Olmsted County, MN, between 2011 and 2022, and to characterize clinical, radiographic, and pathologic characteristics of these patients.
METHODS METHODS
This was a retrospective examination of data from a population-based cohort of patients with PPA and PPAOS prospectively identified in Olmsted County, MN, from 2011 to 2022. The incidence of PPA among adults (older than 18 years) was calculated for Olmsted County as the number of patients per 100,000 person-years during the study period. The adult population of Olmsted County was determined by the annual catchment population reported by the Rochester Epidemiological Project for each year 2011-2022. A behavioral neurologist verified the clinical diagnoses and determined subtypes.
RESULTS RESULTS
We identified 10 patients (60% female) within the study period (median age of symptoms onset: 70 years; range: 66-73), 8 with PPA and 2 with PPAOS. Of the 8 patients with PPA (6 female patients, 2 male patients), 2 met criteria for non-fluent variant PPA (nfvPPA), 3 for logopenic variant PPA (lvPPA), and 3 for semantic variant (svPPA). Speech evaluation confirmed the clinical diagnoses in all patients and all showed typical imaging findings consistent with their respective subtype. Six patients (2 PPAOS, 2 nfvPPA, 2 lvPPA) died and 3 underwent autopsy (2 PPAOS, 1 nfvPPA), confirming the pathologic diagnosis of progressive supranuclear palsy. The incidence of PPA + PPAOS was 0.70 persons per 100,000 person-years (95% CI 0.34-1.29 persons per 100,000) during the study period. The incidence of PPAOS was 0.14 persons per 100,000 person-years (95% CI 0.02-0.55 persons per 100,000), whereas for the 8 patients with PPA, the incidence was 0.56 persons per 100,000 person-years (95% CI 0.24-1.10 cases per 100,000). The incidence of nfvPPA was 0.14 persons per 100,000 person-years (95% CI 0.02-0.55), 0.21 persons per 100,000 person-years (95% CI 0.04-0.61) for lvPPA, and 0.21 persons per 100,000 person-years (95% CI 0.04-0.61) for svPPA.
DISCUSSION CONCLUSIONS
As a group, PPA and PPAOS are a relatively rare group of diseases. PPAOS has a slightly lower incidence than PPA as a group but similar incidence to the individual PPA variants.

Identifiants

pubmed: 39079073
doi: 10.1212/WNL.0000000000209693
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e209693

Auteurs

Pierpaolo Turcano (P)

From the Division of Speech Pathology (J.R.D.), Department of Neurology (P.T., K.A.J., R.S.) and Departments of Radiology (J.L.W.), Psychiatry and Psychology (Neuropsychology) (M.M.M.), and Health Sciences Research (A.M.), Mayo Clinic, Rochester, MN.

Jennifer L Whitwell (JL)

From the Division of Speech Pathology (J.R.D.), Department of Neurology (P.T., K.A.J., R.S.) and Departments of Radiology (J.L.W.), Psychiatry and Psychology (Neuropsychology) (M.M.M.), and Health Sciences Research (A.M.), Mayo Clinic, Rochester, MN.

Joseph R Duffy (JR)

From the Division of Speech Pathology (J.R.D.), Department of Neurology (P.T., K.A.J., R.S.) and Departments of Radiology (J.L.W.), Psychiatry and Psychology (Neuropsychology) (M.M.M.), and Health Sciences Research (A.M.), Mayo Clinic, Rochester, MN.

Mary M Machulda (MM)

From the Division of Speech Pathology (J.R.D.), Department of Neurology (P.T., K.A.J., R.S.) and Departments of Radiology (J.L.W.), Psychiatry and Psychology (Neuropsychology) (M.M.M.), and Health Sciences Research (A.M.), Mayo Clinic, Rochester, MN.

Aidan Mullan (A)

From the Division of Speech Pathology (J.R.D.), Department of Neurology (P.T., K.A.J., R.S.) and Departments of Radiology (J.L.W.), Psychiatry and Psychology (Neuropsychology) (M.M.M.), and Health Sciences Research (A.M.), Mayo Clinic, Rochester, MN.

Keith A Josephs (KA)

From the Division of Speech Pathology (J.R.D.), Department of Neurology (P.T., K.A.J., R.S.) and Departments of Radiology (J.L.W.), Psychiatry and Psychology (Neuropsychology) (M.M.M.), and Health Sciences Research (A.M.), Mayo Clinic, Rochester, MN.

Rodolfo Savica (R)

From the Division of Speech Pathology (J.R.D.), Department of Neurology (P.T., K.A.J., R.S.) and Departments of Radiology (J.L.W.), Psychiatry and Psychology (Neuropsychology) (M.M.M.), and Health Sciences Research (A.M.), Mayo Clinic, Rochester, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH